Neurocrine Biosciences (NBIX) Convertible Debt (2017 - 2023)

Neurocrine Biosciences has reported Convertible Debt for 7 years, with the latest figure at $169.5 million in Q1 2023.

• For the quarter ending Q1 2023, Convertible Debt fell 55.12% year-over-year to $169.5 million; the trailing twelve-month figure through Mar 2023 stood at $169.5 million (down 55.12% YoY), and the FY2021 full-year result was $335.1 million, up 5.41% from the prior year.
• Convertible Debt for Q1 2023 stood at $169.5 million, roughly flat from $169.0 million in the prior quarter.
• The five-year high for Convertible Debt was $414.1 million in Q1 2020, with the low at $169.0 million in Q2 2022.
• Historically, Convertible Debt has averaged $329.8 million across 5 years, with a median of $332.9 million in 2021.
• Annual changes were most pronounced in 2022 — Convertible Debt gained 17.3% — and 2023, when it plunged 55.12%.
• Neurocrine Biosciences' Convertible Debt stood at $403.6 million in 2019, then fell by 21.23% to $317.9 million in 2020, then rose by 5.41% to $335.1 million in 2021, then slumped by 49.57% to $169.0 million in 2022, then gained by 0.3% to $169.5 million in 2023.
• The last three Convertible Debt figures came in at $169.5 million (Q1 2023), $169.0 million (Q2 2022), and $377.7 million (Q1 2022), per Business Quant data.